Theravance Biopharma to Present at the 40th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Theravance Biopharma (NASDAQ: TBPH) will present at the J.P. Morgan 40th Annual Healthcare Conference on January 13, 2022, at 12:00 PM ET. The webcast can be accessed on the company's website under the Investors section, and a replay will be available for 30 days. Theravance focuses on respiratory medicines, boasting FDA-approved YUPELRI® for COPD. The company is committed to developing transformative therapies to improve respiratory health.

DUBLIN, Jan. 5, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a biopharmaceutical company primarily focused on the discovery, development and commercialization of respiratory medicines, will present as follows: 

• J.P. Morgan 40^th Annual Healthcare Conference on Thursday, January 13, at 12:00 pm ET (9:00 am PT/5:00 pm GMT)

Webcast of the event may be accessed by visiting Theravance.com, under the Investors section, Presentations and Events. Replay of the webcast will be archived on the Company's website for 30 days.

About Theravance Biopharma

Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the discovery, development and commercialization of respiratory medicines. Its core purpose is to create medicines that help improve the lives of patients suffering from respiratory illness.

In pursuit of its purpose, Theravance Biopharma leverages decades of respiratory expertise to discover and develop transformational medicines that make a difference. These efforts have led to the development of FDA-approved YUPELRI^® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its respiratory pipeline of internally discovered programs is targeted to address significant patient respiratory needs.

Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY.

For more information, please visit www.theravance.com.

THERAVANCE BIOPHARMA^®, THERAVANCE^®, and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the US and certain other countries).

YUPELRI^® is a registered trademark of Mylan Specialty L.P., a Viatris Company. Trademarks, trade names or service marks of other companies appearing on this press release are the property of their respective owners.

Contact Information:
Contact: Gail B. Cohen
Corporate Communications / 917-214-6603

View original content to download multimedia:https://www.prnewswire.com/news-releases/theravance-biopharma-to-present-at-the-40th-annual-jp-morgan-healthcare-conference-301454139.html

SOURCE Theravance Biopharma, Inc.

FAQ

When is Theravance Biopharma presenting at the J.P. Morgan Healthcare Conference?

Theravance Biopharma will present on January 13, 2022, at 12:00 PM ET.

How can I access the Theravance Biopharma conference presentation?

The conference presentation can be accessed via the webcast on Theravance's website under the Investors section.

What is the focus of Theravance Biopharma?

Theravance Biopharma primarily focuses on the discovery, development, and commercialization of respiratory medicines.

What product does Theravance Biopharma have approved for COPD?

Theravance Biopharma has developed YUPELRI® (revefenacin) for the maintenance treatment of COPD.

Where can I find more information about Theravance Biopharma?

More information can be found on the company's website at www.theravance.com.